The challenge of access to care for soft tissue sarcomas bridging pediatric and adult age: The Italian pediatric oncology view

Expert Review of Anticancer Therapy

Volumn 12, Issue 2, 2012, Pages 243-254

  Ferrari, Andrea ^a   Bisogno, Gianni ^b   Meazza, Cristina ^a   De Pava, Marco Vajna ^a   Sultan, Iyad ^c   De Salvo, Gian Luca ^d   Clerici, Carlo Alfredo ^a,e   Veneroni, Laura ^a,e   Casanova, Michela ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

^c KING HUSSEIN CANCER CENTER   (Jordan)

^d VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^e UNIVERSITY OF MILAN   (Italy)

Author keywords

access to care; adolescents; age; clinical trials; rhabdomyosarcoma; soft tissue sarcomas; synovial sarcoma; young adults

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; IFOSFAMIDE; VINCRISTINE;

ADULT; AGE; AGE SPECIFIC CARE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOSENSITIVITY; CHILD CARE; HEALTH CARE ACCESS; HEALTH CARE UTILIZATION; HUMAN; INTERHOSPITAL COOPERATION; ITALY; METASTASIS FREE SURVIVAL; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT CARE; REVIEW; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; SURVIVAL RATE; SYNOVIAL SARCOMA;

ADULT; AGE FACTORS; CHILD; DISEASE MANAGEMENT; HEALTH SERVICES ACCESSIBILITY; HUMANS; ITALY; MEDICAL ONCOLOGY; RHABDOMYOSARCOMA; SARCOMA; SARCOMA, SYNOVIAL; SOFT TISSUE NEOPLASMS; SURVIVAL RATE;

EID: 84856937747     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/era.11.209     Document Type: Review

References (78)

1. Ferrari A Sultan I, Rodriguez-Galindo C et al. Soft tissue sarcoma across the age spectrum: A population-based study from the Surveillance Epidemiology and End Results database. Pediatr. Blood Cancer 57(6), 943-949 (2011).
2. Ferrari A, Gronchi A, Casanova M et al. Synovial sarcoma: A retrospective analysis of 271 patients of all ages treated at a single institution. Cancer 101, 627-634 (2004). (Pubitemid 38970615)
3. Ferrari A, Casanova M. New concepts for the treatment of pediatric nonrhabdomyosarcoma soft tissue sarcomas. Expert Rev. Anticancer Ther. 5(2), 307-318 (2005). (Pubitemid 40553095)
4. Ferrari A. Role of chemotherapy in pediatric nonrhabdomyosarcoma soft-tissue sarcomas. Expert Rev. Anticancer Ther. 8(6), 929-938 (2008).
5. Okcu MF, Munsell M, Treuner J et al. Synovial sarcoma of childhood and adolescence: A multicenter, multivariate analysis of outcome. J. Clin. Oncol. 21, 1602-1611 (2003). (Pubitemid 46594115)
6. Brecht IB, Ferrari A, Int-Veen C et al. Grossly-resected synovial sarcoma treated by the German and Italian pediatric soft tissue sarcoma cooperative group: Discussion on the role of adjuvant therapies. Pediatr. Blood Cancer 46, 11-17 (2006). (Pubitemid 41779312)
7. Ferrari A, Bisogno G, Alaggio G et al. Synovial sarcoma of children and adolescents: The prognostic role of axial sites. Eur. J. Cancer 44, 1202-1209 (2008).
8. Brennan B, Stevens M, Kelsey A, Stiller CA. Synovial sarcoma in childhood and adolescence: A retrospective series of 77 patients registered by the Children's Cancer and Leukaemia Group between 1991 and 2006. Pediatr. Blood Cancer 55, 85-90 (2010).
9. Orbach D, Dowell HM, Rey A et al. Sparing strategy does not compromise prognosis in pediatric localized synovial sarcoma: Experience of the International Society of Pediatric Oncology, Malignant Mesenchymal Tumors (SIOP-MMT) Working Group. Pediatr. Blood Cancer 57(7), 1130-1136 (2011).
10. Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: Meta-analysis of individual data. Lancet 350, 1647-1654 (1997).
11. Sultan I, Rodriguez-Galindo C, Saab R et al. Comparing children and adults with synovial sarcoma in the Surveillance, Epidemiology and End Results Program, 1983 to 2005: An analysis of 1268 patients. Cancer 115, 3537-3547 (2009).
12. Lewis JJ, Antonescu CR, Leung DH et al. Synovial sarcoma: A multivariate analysis of prognostic factors in 112 patients with primary localized tumours of the extremity. J. Clin. Oncol. 18, 2087-2094 (2000). (Pubitemid 30324362)
13. Trassard M, Le Doussal V, Hacene K et al. Prognostic factors in localized primary synovial sarcoma: A multicenter study of 128 adult patients. J. Clin. Oncol. 19, 525-534 (2001). (Pubitemid 32112867)
14. Spurrell EL, Fisher C, Thomas JM, Judson IR. Prognostic factors in advanced synovial sarcoma: An analysis of 104 patients treated at the Royal Marsden Hospital. Ann. Oncol. 16(3), 437-444 (2005). (Pubitemid 40458321)
15. Eilber FC, Brennan MF, Eilber FR et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann. Surg. 246(1), 105-113 (2007). (Pubitemid 47012214)
16. Canter RJ, Qin LX, Maki RG et al. A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin. Cancer Res. 14(24), 8191-8197 (2008).
17. Italiano A, Penel N, Robin YM et al. Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: A study of the French Sarcoma Group. Ann. Oncol. 20(3), 425-430 (2009).
18. Palmerini E, Staals EL, Alberghini M et al. Synovial sarcoma: Retrospective analysis of 250 patients treated at a single institution. Cancer 115(13), 2988-2998 (2009).
19. Al-Hussaini H, Hogg D, Blackstein ME et al. Clinical features, treatment, and outcome in 102 adult and pediatric patients with localized high-grade synovial sarcoma. Sarcoma 2011, 231789 (2011).
20. Guadagnolo BA, Zagars GK, Ballo MT et al. Long-term outcomes for synovial sarcoma treated with conservation surgery and radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 69(4), 1173-1180 (2007). (Pubitemid 47625848)
21. Bleyer A, Montello M, Budd T, Saxman S. National survival trends of young adults with sarcoma: Lack of progress is associated with lack of clinical trial participation. Cancer 103, 1891-1897 (2005). (Pubitemid 40563262)
22. Burke ME, Albritton K, Marina N. Challenges in the recruitment of adolescents and young adults to cancer clinical trials. Cancer 110, 2385-2393 (2007). . Discusses the problem of access to care for adolescents with cancer. (Pubitemid 350174923)
23. Ferrari A, Bleyer A. Participation of adolescents with cancer in clinical trials. Cancer Treat. Rev. 33, 603-608 (2007). (Pubitemid 350047371)
24. Ferrari A, Casanova M, Meazza C et al. Adult-type soft tissue sarcomas in pediatric age: Experience at the Istituto Nazionale Tumori in Milan. J. Clin. Oncol. 23, 4021-4030 (2005). (Pubitemid 46211306)
25. Ferrari A, Dileo P, Casanova M et al. Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. Cancer 98, 571-580 (2003). . Discusses adult rhabdomyosarcoma stratified according to delivered treatment compared with pediatric treatment guidelines. (Pubitemid 36885998)
26. Sultan I, Qaddoumi I, Yaser S, Rodriguez- Galindo C, Ferrari A. Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: An analysis of 2,600 patients. J. Clin. Oncol. 27(20), 3391-3397 (2009).
27. Ferrari A, Casanova M. Current chemotherapeutic strategies for rhabdomyosarcoma. Expert Rev. Anticancer Ther. 5(2), 283-294 (2005). (Pubitemid 40553093)
28. Raney RB, Anderson JR, Barr FG et al. Rhabdomyosarcoma and undifferentiated sarcoma in the first two decades of life: A selective review of intergroup rhabdomyosarcoma study group experience and rationale for Intergroup Rhabdomyosarcoma Study V. J. Pediatr. Hematol. Oncol. 23(4), 215-220 (2001). (Pubitemid 32524925)
29. Stevens MC, Rey A, Bouvet N et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: Third study of the International Society of Paediatric Oncology - SIOP Malignant Mesenchymal Tumor 89. J. Clin. Oncol. 23(12), 2618-2628 (2005). (Pubitemid 46179450)
30. Arndt CA, Stoner JA, Hawkins DS et al. Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: Children's Oncology Group Study D9803. J. Clin. Oncol. 27, 5182-5188 (2009).
31. Bisogno G, De Rossi C, Gamboa Y et al. Improved survival for children with parameningeal rhabdomyosarcoma: Results from the AIEOP soft tissue sarcoma committee. Pediatr. Blood Cancer 50, 1154-1158 (2008). (Pubitemid 351555537)
32. Sultan I, Ferrari A. Selecting multimodal therapy for rhabdomyosarcoma. Expert Rev. Anticancer Ther. 10(8), 1285-1301 (2010).
33. Meza JL, Anderson J, Pappo AS, Meyer WH. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: The Children's Oncology Group. J. Clin. Oncol. 24, 3844-3851 (2006). (Pubitemid 46630730)
34. Joshi D, Anderson JR, Paidas C et al. Age is an independent prognostic factor in rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Pediatr. Blood Cancer 42, 64-73 (2004). (Pubitemid 38173459)
35. Oberlin O, Rey A, Lyden E et al. Prognostic factors in metastatic rhabdomyosarcomas: Results of a pooled analysis from United States and European cooperative groups. J. Clin. Oncol. 26, 2384-2389 (2008).
36. Bisogno G, Compostella A, Ferrari A et al. Rhabdomyosarcoma in adolescents: A report from the AIEOP Soft Tissue Sarcoma Committee. Cancer doi:10.1002/ cncr.26355 (2011) (Epub ahead of print).
37. Veal GJ, Hartford CM, Stewart CF. Clinical pharmacology in the adolescent oncology patient. J. Clin. Oncol. 28, 4790-4799 (2010).
38. Hawkins WG, Hoos A, Antonescu CR et al. Clinicopathologic analysis of patients with adult rhabdomyosarcoma. Cancer 91, 794-803 (2001). (Pubitemid 32173305)
39. Esnaola NF, Rubin BP, Baldini EH et al. Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma. Cancer 91, 794-803 (2001).
40. Little DJ, Ballo MT, Zagars GK et al. Adult rhabdomyosarcoma: Outcome following multimodality treatment. Cancer 95, 377-388 (2002). (Pubitemid 34787604)
41. La Quaglia MP, Heller G, Ghavimi F et al. The effect of age at diagnosis on outcome in rhabdomyosarcoma. Cancer 73, 109-117 (1994). (Pubitemid 24012730)
42. Bleyer A, Tejeda H, Murphy SB et al. National cancer clinical trials: Children have equal access; adolescents do not. J. Adolesc. Health 21, 366-373 (1997). (Pubitemid 27514842)
43. Liu L, Krailo M, Reaman GH, Bernstein L. Childhood cancer patients' access to cooperative group cancer programs: A population-based study. Cancer 97(5), 1339-1345 (2003). (Pubitemid 36237322)
44. Bleyer A, Barr R. Highlights and challenges. In:Cancer Epidemiology in Older Adolescents and Young Adults 15 to 29 Years of Age, Including SEER Incidence and Survival 1975-2000. Bleyer A, O'Leary M, Barr R, Ries LAG (Eds). National Cancer Institute, NIH Pub. No. 06-5767, Bethesda, MD, USA (2006). .. Comprehensive overview on the challenge of adolescent and young adult oncology.
45. Bleyer A, Budd T, Montello M. Adolescents and young adults with cancer: The scope of the problem and criticality of clinical trials. Cancer 107, 1645-1655 (2006). (Pubitemid 44537071)
46. Ferrari A, Montello M, Budd T et al. The challenges of clinical trials for adolescents and young adults with cancer. Pediatr. Blood Cancer 50, 1101-1104 (2008). (Pubitemid 351500162)
47. Fern L, Davies S, Eden T et al. Rates of inclusion of teenagers and young adults in England into National Cancer Research Network clinical trials: Report from the National Cancer Research Institute (NCRI) Teenage and Young Adult Clinical Studies Development Group. Br. J. Cancer 99(12), 1967-1974 (2008).
48. Desandes E, Lacour B, Sommelet D et al. Cancer adolescent pathway in France between 1988 and 1997. Eur. J. Oncol. Nurs. 11(1), 74-81 (2007).
49. Ferrari A, Dama E, Pession A et al. Adolescents with cancer in Italy: Entry into the national cooperative paediatric oncology group AIEOP trials. Eur. J. Cancer 45(3), 328-334 (2009). . The Italian picture on access to care of adolescents with cancer.
50. Ferrari A, Meazza C, Vajna de Pava M et al. Two cases of adolescents with paratesticular rhabdomyosarcoma inadequately treated: The problem of referral. J. Adol. Young Adult Oncol. (2011) (In Press).
51. Ferrari A, Miceli R, Casanova M et al. Symptom interval in children and adolescents with soft tissue sarcomas. Cancer 116, 177-183 (2010).
52. Dang-Tan T, Trottier H, Mery LS et al. Delays in diagnosis and treatment among children and adolescents with cancer in Canada. Pediatr. Blood Cancer 51(4), 468-474 (2008).
53. Martin S, Ulrich C, Munsell M, Taylor S, Lange G, Bleyer A. Delays in cancer diagnosis in underinsured young adults and older adolescents. Oncologist 12, 816-824 (2007). (Pubitemid 47328225)
54. Ziv A, Boulet JR, Slap GB. Utilization of physician offices by adolescents in the United States. Pediatrics 104, 35-42 (1999). (Pubitemid 29315844)
55. Andersen BL, Cacioppo JT. Delay in seeking a cancer diagnosis: Delay stages and psychophysiological comparison processes. Br. J. Psychol. 34(Pt 1), 33-52 (1995).
56. Morgan S, Davies S, Palmer S, Plaster M. Sex, drugs, and rock 'n' roll: Caring for adolescents and young adults with cancer. J. Clin. Oncol. 28(32), 4825-4830 (2010).
57. Gronchi A, Miceli R, Colombo C et al. Primary extremity soft tissue sarcomas: Outcome improvement over time at a single institution. Ann. Oncol. 22(7), 1675-1681 (2011).
58. Gronchi A, Frustaci S, Mercuri M et al. Localized, high-risk soft tissue sarcomas (STS) of the extremities and trunk wall in adults: Three versus five cycles of full-dose anthracyclin and ifosfamide adjuvant chemotherapy: A Phase III randomized trial from the Italian Sarcoma Group (ISG) and Spanish Sarcoma Group (GEIS). J. Clin. Oncol. 28, 15s (2010) (Abstract 10003).
59. Stacchiotti S, Negri T, Zaffaroni N et al. Sunitinib in advanced alveolar soft part sarcoma: Evidence of a direct antitumor effect. Ann. Oncol. 22(7), 1682-1690 (2011).
60. Gronchi A, Bui BN, Bonvalot S et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann. Oncol. doi:10.1093/annonc/mdr265 (2011) (Epub ahead of print).
61. Bleyer A, Morgan S, Barr R. Proceedings of a workshop: Bridging the gap in care and addressing participation in clinical trials. Cancer 107(Suppl. 7), 1656-1658 (2006). (Pubitemid 44537072)
62. Ferrari A, Thomas DM, Franklin A et al. Starting an AYA program: Some success stories and some obstacles to overcome. J. Clin. Oncol. 28(32), 4850-4857 (2010). .. Overview of the programs dedicated to adolescents and young adults with cancer: Key issues for developing a program.
63. Whiteson M. The Teenage Cancer Trust - advocating a model for teenage cancer services. Eur. J. Cancer 39, 2688-2693 (2003). (Pubitemid 37468312)
64. Lewis IJ, Fallon S, van Dongen-Melman J, Barr R. Cancer and the adolescent: The Second Teenage Cancer Trust International Conference, Royal College of Physicians, London, England, March 2001. Med. Pediatr. Oncol. 39(3), 198-201 (2002). (Pubitemid 34827571)
65. Eden T. Keynote comment: Challenges of teenage and young-adult oncology. Lancet Oncol. 7, 612-613 (2006). (Pubitemid 44123572)
66. US Department of Health and Human Services. Closing The Gap: Research And Care Imperatives For Adolescents And Young Adults With Cancer. NIH publication 06-6067, Bethesda, MD, USA (2006).
67. Mathews-Bradshaw B, Johnson R, Kaplan S et al. The history and accomplishments of the LIVESTRONG Youg Adult Alliance. J. Adol. Young Adult Oncol. 1(1), 43-47 (2011).
68. Barr R, Eden T. International working group on adolescent/teenage and young adult oncology. Pediatr. Blood Cancer 50, 1089 (2008). (Pubitemid 351500158)
69. Ferrari A, Aricó M, Dini G et al. Upper-age limits for accessing pediatric oncology centers in Italy: A barrier preventing adolescents with cancer from entering national cooperative AIEOP trials. Pediatr. Hematol. Oncol. doi:10.3109/08880018.20 11.572963 (2011) (Epub ahead of print).
70. Ferrari A, Clerici CA, Casanova M et al. The Youth Project at the Istituto Nazionale Tumori in Milan. Tumori (2011) (In Press).
71. Ferrari A. Harmonizing adult and pediatric approaches to the treatment of soft tissue sarcoma. Expert Rev. Anticancer Ther. 9(11), 1541-1543 (2009).
72. Thomas DM, Albritton KH, Ferrari A. Adolescent and young adult oncology: An emerging field. J. Clin. Oncol. 28(32), 4781-4782 (2010).
73. Bleyer A. The Quid Pro Quo of pediatric versus adult services for older adolescent cancer patients. Pediatr. Blood Cancer 54(2), 238-241 (2010).
74. Klein-Geltink J, Shaw AK, Morrison HI et al. Use of paediatric versus adult oncology treatment centres by adolescents 15-19 years old: The Canadian Childhood Cancer Surveillance and Control Program. Eur. J. Cancer 41(3), 404-410 (2005). (Pubitemid 40187212)
75. Boissel N, Auclerc MF, Lheritier V et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J. Clin. Oncol. 21, 774-780 (2003). (Pubitemid 46606434)
76. Ramanujachar R, Richards S, Hann I, Webb D. Adolescents with acute lymphoblastic leukaemia: Emerging from the shadow of paediatric and adult treatment protocols. Pediatr. Blood Cancer 43(6), 748-756 (2006). (Pubitemid 44476750)
77. de Bont JM, van der Holt B, Dekker AW et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric versus adult ALL protocols in The Netherlands. Leukemia 18, 2032-2053 (2004).
78. Paulussen S, Ahrens S, Juergens HF. Cure rates in Ewing tumor patients aged over 15 years are better in pediatric oncology units. Results of GPOH CESS/EICESS studies. Proc. Am. Soc. Clin. Oncol. 22, 816 (2003).